Transcutaneous Vagal Nerve Stimulation to Prevent Tachyarrhythmias in Patients Early Following Myocardial Infarction

NCT ID: NCT05750108

Last Updated: 2023-03-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-30

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Among patients early following ST-segment (ST) elevation myocardial infarction, transcutaneous vagus nerve stimulation is associated with a reduce of the burden of premature ventricular contractions in the first 40 days post-myocardial infarction (MI).

The above hypothesis will be tested with a randomized, prospective, parallel, single-blind clinical trial. The expected study duration is approximately 12 months from the time the first subject is enrolled (planned for June 2023) to the time of study's termination date (December 2024). Patient enrollment is planned to take place at two major centers in Greece. The researchers will obtain approval by the institutional review board (IRB).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Tachyarrhythmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Transcutaneous Vagal Nerve Stimulation

Group Type ACTIVE_COMPARATOR

Parasym device (active, current (mA) < discomfort threshold)

Intervention Type DEVICE

Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.

Sham Transcutaneous Vagal Nerve Stimulation

Group Type SHAM_COMPARATOR

Parasym device (sham, current (mA) = 0)

Intervention Type DEVICE

Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Parasym device (active, current (mA) < discomfort threshold)

Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.

Intervention Type DEVICE

Parasym device (sham, current (mA) = 0)

Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients aged ≥18 years
* ST-elevation myocardial infarction which is treated with a primary percutaneous coronary intervention
* Signed written informed consent by the patient for participation in the study and agreement to comply with the medication and the follow-up schedule

Exclusion Criteria

A patient will be excluded from the study if one or more of all the following criteria are present:

* \< 3 months after prior ablation
* Patients on amiodarone
* Patients with known thyroid issues, on renal-dialysis
* Life expectancy of \< 12 months
* Complex congenital heart disease
* Cardiogenic shock
* Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)
* Known channelopathy such as Brugada syndrome, long QT syndrome, or Catecholaminergic monomorphic ventricular tachycardia
* Symptomatic sinus bradycardia or sinus node dysfunction at baseline without an implantable pacemaker
* Complete heart block or trifascicular block without an implantable pacemaker
* Recurrent vasovagal syncope
* Pre-existing implantable cardioverter-defibrillator (ICD)
* Secondary prevention indication for an ICD (i.e. sustained ventricular arrhythmias occurring more than 48 hours after qualifying myocardial infarction (patients with ventricular arrhythmias occurring ≤48 hours of myocardial infarction, or with non-sustained ventricular tachycardia at any time, are not excluded))
* On the heart transplant list
* Recurrent unstable angina despite revascularisation (defined as ongoing chest pain or ischemic symptoms at rest or with minimal exertion despite adequate treatment with anti-anginal medications)
* Congestive heart failure New York Heart Association class IV, defined as shortness of breath at rest, which is refractory to medical treatment (not responding to treatment)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hippocration General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Konstantinos Tsioufis

Principal Investigator, Senior cardiology expert. Prof. Konstantinos P. Tsioufis, MD, PhD, FESC, FACC, Professor of Cardiology, Director of 1st Department of Cardiology, Hippokratio Hospital, University of Athens

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Rhythm Institute, University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Site Status

First Department of Cardiology, Hippocration General Hospital, National and Kapodistrian University of Athens

Athens, Attica, Greece

Site Status

Athens Heart Center Amarousion

Athens, Attica, Greece

Site Status

Biomedical Engineering, Khalifa University of Science and Technology

Abu Dhabi, , United Arab Emirates

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Greece United Arab Emirates

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Konstantinos Tsioufis, Professor

Role: CONTACT

2132088000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stavros Stavrakis, MD, PhD

Role: primary

Konstantinos Tsioufis, Professor

Role: primary

2132088000

Dimitrios Tsiachris, MD

Role: primary

Leontios Hadjileontiadis

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EARLY-VAGUS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Functional Substrate-Only Guided VT Ablation
NCT06464315 NOT_YET_RECRUITING NA